{"id":359331,"date":"2025-08-30T08:48:13","date_gmt":"2025-08-30T08:48:13","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-nuvalent\/"},"modified":"2025-08-30T08:48:13","modified_gmt":"2025-08-30T08:48:13","slug":"how-to-buy-nuvalent","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/","title":{"rendered":"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-359331","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Nuvalent, Inc. (NUVL) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve portf\u00f6y\u00fcn\u00fcz i\u00e7in b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Nuvalent, Inc. (NUVL) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve portf\u00f6y\u00fcn\u00fcz i\u00e7in b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Portf\u00f6y\u00fcn\u00fcze ileri teknoloji bir biyoteknoloji hissesi eklemeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? Nuvalent, Inc. (NUVL), tedaviye diren\u00e7li kanserlere y\u00f6nelik yenilik\u00e7i \u00fcr\u00fcn hatt\u0131yla hassas kanser tedavisinin gelece\u011fini temsil ediyor. Klinik a\u015famadaki bu \u015firket, terapileri klinik denemelerde ba\u015far\u0131l\u0131 olursa ve FDA onay\u0131 al\u0131rsa size \u00f6nemli getiriler sa\u011flayabilir. NUVL'nin neden dikkatinizi hak etti\u011fini ve nas\u0131l hissedar olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Portf\u00f6y\u00fcn\u00fcze ileri teknoloji bir biyoteknoloji hissesi eklemeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? Nuvalent, Inc. (NUVL), tedaviye diren\u00e7li kanserlere y\u00f6nelik yenilik\u00e7i \u00fcr\u00fcn hatt\u0131yla hassas kanser tedavisinin gelece\u011fini temsil ediyor. Klinik a\u015famadaki bu \u015firket, terapileri klinik denemelerde ba\u015far\u0131l\u0131 olursa ve FDA onay\u0131 al\u0131rsa size \u00f6nemli getiriler sa\u011flayabilir. NUVL'nin neden dikkatinizi hak etti\u011fini ve nas\u0131l hissedar olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Nuvalent Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>30 A\u011fustos 2025 itibar\u0131yla Nuvalent, Inc. (NUVL) NASDAQ borsas\u0131nda hisse ba\u015f\u0131na <strong>74,93 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse, klinik a\u015famadaki biyoteknoloji \u015firketlerine \u00f6zg\u00fc ola\u011fan\u00fcst\u00fc volatilite g\u00f6sterdi; 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 55,54 $ ile 113,51 $ aras\u0131nda de\u011fi\u015fiyor - bu, d\u00fc\u015f\u00fck ve y\u00fcksek fiyatlar aras\u0131nda %100'den fazla fark demek!<\/p> <p><strong>Takviminize Not Edin: 11 Kas\u0131m 2025<\/strong>, NUVL yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirket bu tarihte 2025 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak ve ge\u00e7mi\u015fte bu t\u00fcr raporlar hisse fiyat\u0131nda dramatik hareketlere yol a\u00e7abiliyor.<\/p> <h3>Kazan\u00e7 Raporlar\u0131n\u0131n NUVL Hissesi \u00dczerindeki Etkisi<\/h3> <p>Son d\u00f6neme bak\u0131ld\u0131\u011f\u0131nda, \u00f6nemli duyurular etraf\u0131nda belirgin fiyat hareketleri g\u00f6r\u00fcl\u00fcyor:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>7 A\u011fustos 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>78,50 $<\/td><td>-%4,5 (EPS tahminleri ka\u00e7\u0131r\u0131ld\u0131)<\/td><\/tr> <tr><td>8 May\u0131s 2025<\/td><td>Klinik Deneme G\u00fcncellemesi<\/td><td>72,30 $<\/td><td>+%18,2 (pozitif veriler)<\/td><\/tr> <tr><td>27 \u015eubat 2025<\/td><td>2024 4. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>68,90 $<\/td><td>+%9,8 (\u00fcr\u00fcn hatt\u0131 ilerlemesi)<\/td><\/tr> <tr><td>9 Kas\u0131m 2024<\/td><td>FDA Ba\u015fvuru Haberi<\/td><td>65,40 $<\/td><td>+%22,1 (kademeli NDA kabul\u00fc)<\/td><\/tr> <tr><td>8 A\u011fustos 2024<\/td><td>2024 2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>62,10 $<\/td><td>+%11,3 (g\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131 g\u00fcncellemeleri)<\/td><\/tr> <tr><td>10 May\u0131s 2024<\/td><td>Faz 1 Verileri<\/td><td>58,20 $<\/td><td>+%6,8 (cesaret verici sonu\u00e7lar)<\/td><\/tr> <\/tbody> <\/table> <p><strong>E\u011filim Analizi<\/strong>: Pozitif klinik deneme g\u00fcncellemeleri ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 genellikle en b\u00fcy\u00fck kazan\u00e7lar\u0131 (%18-22) getirirken, kazan\u00e7 ka\u00e7\u0131rmalar\u0131 ge\u00e7ici %4-5 d\u00fc\u015f\u00fc\u015flere neden oluyor. Bu desen, NUVL yat\u0131r\u0131mc\u0131lar\u0131n\u0131n \u00e7eyreklik finansallardan \u00e7ok klinik geli\u015fmelere odaklanmas\u0131 gerekti\u011fini g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2> <p>Nuvalent hisseleri son alt\u0131 ayda <strong>%27,8 art\u0131\u015f<\/strong> ya\u015fad\u0131, ancak yolculuk sorunsuz de\u011fildi:<\/p> <ul> <li><strong>\u015eubat 2025<\/strong>: 62,50 $ - Tatil sonras\u0131 konsolidasyon d\u00f6nemi<\/li> <li><strong>Mart 2025<\/strong>: 71,80 $ - ALKAZAR Faz 3 deneme ba\u015flang\u0131c\u0131yla art\u0131\u015f<\/li> <li><strong>Nisan 2025<\/strong>: 68,20 $ - Mart rallisi sonras\u0131 kar realizasyonu<\/li> <li><strong>May\u0131s 2025<\/strong>: 83,40 $ - ASCO toplant\u0131s\u0131nda klinik veri sunumu<\/li> <li><strong>Haziran 2025<\/strong>: 76,10 $ - Piyasa genelinde biyoteknoloji sekt\u00f6r\u00fc d\u00fczeltmesi<\/li> <li><strong>Temmuz 2025<\/strong>: 79,60 $ - FDA RTOR program\u0131na kat\u0131l\u0131m heyecan\u0131<\/li> <li><strong>A\u011fustos 2025<\/strong>: 74,93 $ - 2. \u00e7eyrek kazan\u00e7 ka\u00e7\u0131rmas\u0131 hevesi azaltt\u0131<\/li> <\/ul> <p>Volatilitenin sebebi nedir? NUVL, \"OnTarget 2026\" stratejisini birden fazla klinik d\u00f6n\u00fcm noktas\u0131yla uyguluyor. \u015eirket, neladalkib ile standart tedavi alectinib'i kar\u015f\u0131la\u015ft\u0131ran kritik ALKAZAR Faz 3 denemesini ba\u015flat\u0131rken, zidesamtinib i\u00e7in kademeli NDA ba\u015fvurusunu da ilerletiyor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Yolu<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve \u00fcr\u00fcn hatt\u0131 ilerlemesine g\u00f6re beklentiler \u015funlar:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 95-110 $ (FDA ba\u015fvuru tamamlanmas\u0131 ve klinik veri a\u00e7\u0131klamalar\u0131) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/li> <li><strong>2026<\/strong>: 130-160 $ (Olas\u0131 ilk FDA onay\u0131 ve ticarile\u015fme lansman\u0131)<\/li> <li><strong>2028<\/strong>: 220-280 $ (\u00c7oklu \u00fcr\u00fcn lansmanlar\u0131 ve pazar geni\u015flemesi)<\/li> <li><strong>2030<\/strong>: 350-450 $ (K\u00f6kl\u00fc ticari varl\u0131k ve \u00fcr\u00fcn hatt\u0131 olgunla\u015fmas\u0131)<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: NUVL, klasik y\u00fcksek risk-y\u00fcksek getiri biyoteknoloji f\u0131rsat\u0131n\u0131 temsil ediyor. 13 analistin al\u0131m tavsiyesi verdi\u011fi ve fiyat hedeflerinin 100 $ ile 140 $ aras\u0131nda de\u011fi\u015fti\u011fi (<a href=\"https:\/\/www.directorstalkinterviews.com\/nuvalent-inc-nuvl-stock-analysis-a-biotech-contender-with-52-potential-upside\/4121213505\">DirectorTalk Interviews<\/a>) konsens\u00fcs, mevcut seviyelerden yakla\u015f\u0131k %52 y\u00fckseli\u015f potansiyeli oldu\u011funu g\u00f6steriyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: NUVL'nin \u00fc\u00e7 \u00f6nc\u00fc aday\u0131 (NVL-520, NVL-655, NVL-330) etkinlik veya g\u00fcvenlik hedeflerini kar\u015f\u0131layamayabilir<\/li> <li><strong>FDA Reddetmesi<\/strong>: Kademeli NDA ba\u015fvurusuna ra\u011fmen FDA ek veri veya \u00e7al\u0131\u015fmalar talep edebilir<\/li> <li><strong>Nakit Yak\u0131m\u0131<\/strong>: -121 milyon $ negatif serbest nakit ak\u0131\u015f\u0131 dikkatli sermaye y\u00f6netimi gerektirir<\/li> <li><strong>Piyasa Volatilitesi<\/strong>: 1,30 beta de\u011feri, genel piyasadan %30 daha volatil oldu\u011fu anlam\u0131na gelir<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>FDA \u0130vmelenmesi<\/strong>: Ger\u00e7ek Zamanl\u0131 Onkoloji \u0130nceleme program\u0131na kat\u0131l\u0131m s\u00fcreci h\u0131zland\u0131r\u0131yor<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131 Derinli\u011fi<\/strong>: \u00dc\u00e7 klinik a\u015fama aday\u0131 birden fazla ba\u015far\u0131 \u015fans\u0131 sunuyor<\/li> <li><strong>Pazar \u0130htiyac\u0131<\/strong>: Tedaviye diren\u00e7li kanserler 15 milyar $'dan fazla pazar f\u0131rsat\u0131 yarat\u0131yor<\/li> <li><strong>Analist Deste\u011fi<\/strong>: 13 analistin oybirli\u011fiyle al\u0131m tavsiyesi<\/li> <li><strong>Nakit Rezervi<\/strong>: 1 milyar $ nakit pozisyonu operasyonlar\u0131 2028'e kadar finanse ediyor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5'inden fazlas\u0131n\u0131 NUVL gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yapmak yerine, birka\u00e7 hafta boyunca k\u00fc\u00e7\u00fck miktarlarda al\u0131m yap\u0131n<\/li> <li><strong>11 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7 tarihini i\u015faretleyin ve \u00f6nemli fiyat hareketlerine kar\u015f\u0131 haz\u0131r olun<\/li> <li><strong>\u00c7e\u015fitlendirin<\/strong>: NUVL'yi daha istikrarl\u0131 sa\u011fl\u0131k hisseleri veya ETF'lerle dengeleyin<\/li> <\/ol> <p>Espiri: \"NUVL ticareti yapmak, bir t\u0131bbi drama izlemek gibidir - bolca gerilim, ara s\u0131ra kalp krizi, ama sezon finali muhte\u015fem olabilir!\"<\/p> <h2>\u2705 Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ listeli hisseler ve par\u00e7al\u0131 hisse sunan bir platform se\u00e7in<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"NUVL\" Aramas\u0131 Yap\u0131n<\/td><td>Sadece \"Nuvalent\" de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Komisyon \u00fccretlerini kontrol edin - i\u015flem de\u011ferinin %1'inden az olmas\u0131na dikkat edin<\/td><\/tr> <tr><td>6<\/td><td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td><td>70 $ destek ve 80 $ diren\u00e7 gibi kritik seviyeleri izleyin<\/td><\/tr> <tr><td>7<\/td><td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td><td>K\u00e2r alaca\u011f\u0131n\u0131z veya zarar kesme yapaca\u011f\u0131n\u0131z zaman\u0131 \u00f6nceden belirleyin<\/td><\/tr> <tr><td>8<\/td><td>Tezinizi Belgeleyin<\/td><td>Duygusal kararlar almamak i\u00e7in neden ald\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td><\/tr> <tr><td>9<\/td><td>\u015eirket Haberlerini Takip Edin<\/td><td>\"Nuvalent\" ve \"NVL-520\" i\u00e7in Google uyar\u0131lar\u0131 kurun<\/td><\/tr> <tr><td>10<\/td><td>\u00c7eyreklik \u0130nceleme Yap\u0131n<\/td><td>Her kazan\u00e7 raporundan sonra yat\u0131r\u0131m\u0131n\u0131z\u0131 yeniden de\u011ferlendirin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Neden Yeni NUVL Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>Nuvalent gibi yenilik\u00e7i \u015firketlere yat\u0131r\u0131m yapmak isteyenler i\u00e7in Pocket Option, yeni ba\u015flayan yat\u0131r\u0131mc\u0131lara m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunuyor:<\/p> <ul> <li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> - Yat\u0131r\u0131m tezini test etmek i\u00e7in c\u00fczdan\u0131n\u0131zda kalan k\u00fc\u00e7\u00fck bir miktarla ba\u015flayabilirsiniz. Bu, NUVL gibi volatil hisselerde yava\u015f yava\u015f yat\u0131r\u0131m yapmak isteyenler i\u00e7in \u00e7ok \u00f6nemli.<\/li> <li><strong>\u015eim\u015fek H\u0131z\u0131nda Do\u011frulama<\/strong> - Tek bir belge ile KYC i\u015flemini bir dakikadan k\u0131sa s\u00fcrede tamamlay\u0131n. Klinik deneme sonu\u00e7lar\u0131 veya FDA duyurular\u0131 gibi zaman hassasiyeti olan f\u0131rsatlarda uzun onay s\u00fcre\u00e7leri nedeniyle f\u0131rsatlar\u0131 ka\u00e7\u0131rmazs\u0131n\u0131z.<\/li> <li><strong>100'den Fazla Para \u00c7ekme Y\u00f6ntemi<\/strong> - Kripto paralardan e-c\u00fczdanlara ve geleneksel banka transferlerine kadar, NUVL potansiyeliniz ger\u00e7ekle\u015fti\u011finde kazan\u00e7lar\u0131n\u0131za eri\u015fimde esneklik sa\u011flar.<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, NUVL pozisyonunuzu ger\u00e7ek zamanl\u0131 grafikler ve haber entegrasyonu ile kolayca takip etmenizi sa\u011flar; b\u00f6ylece yat\u0131r\u0131m\u0131n\u0131z\u0131 etkileyen kritik geli\u015fmelerden haberdar olursunuz.<\/p> <h2>\ud83c\udf0d 2025'te Nuvalent: Hassas Onkoloji \u00d6nc\u00fcs\u00fc<\/h2> <p>Nuvalent, kanser tedavisinde bir devrimin \u00f6nc\u00fcs\u00fcd\u00fcr. \u015eirket sadece ba\u015fka bir kemoterapi ilac\u0131 geli\u015ftirmiyor - mevcut tedavilerin s\u0131n\u0131rlamalar\u0131n\u0131 a\u015fmak i\u00e7in hassas \u015fekilde hedeflenmi\u015f terapiler yarat\u0131yor. Tedaviye diren\u00e7li kanserlerde kinaz hedeflerine odaklanmalar\u0131, onkolojide en b\u00fcy\u00fck kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lardan birini ele al\u0131yor.<\/p> <p>162 \u00e7al\u0131\u015fan\u0131 ve Massachusetts, Cambridge merkezli operasyonlar\u0131yla Nuvalent, bir startup \u00e7evikli\u011fiyle iddial\u0131 klinik programlar\u0131 y\u00fcr\u00fct\u00fcyor; bu programlar kanser bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilir. \u015eirketin \u00f6nc\u00fc \u00fcr\u00fcn adaylar\u0131 ROS1-pozitif NSCLC, ALK-pozitif NSCLC ve HER2-de\u011fi\u015ftirilmi\u015f kanserleri hedefliyor - mevcut tedavilerin diren\u00e7 mekanizmalar\u0131 nedeniyle s\u0131kl\u0131kla ba\u015far\u0131s\u0131z oldu\u011fu alanlar.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Nuvalent bilim insanlar\u0131, zidesamtinib'in yeni bir ROS1-selektif inhibit\u00f6r olarak rasyonel molek\u00fcler tasar\u0131m yakla\u015f\u0131m\u0131n\u0131 nas\u0131l olu\u015fturdu\u011funu g\u00f6steren \u00e7\u0131\u011f\u0131r a\u00e7an bir ara\u015ft\u0131rmay\u0131 Molecular Cancer Therapeutics dergisinde yay\u0131mlad\u0131 (<a href=\"https:\/\/investors.nuvalent.com\/2025-04-29-Nuvalent-Announces-Publication-in-Molecular-Cancer-Therapeutics-Reinforcing-Rational-Molecular-Design-of-Zidesamtinib-as-a-Novel-ROS1-Selective-Inhibitor\">\u015eirket Duyurusu<\/a>). Bu sadece ba\u015fka bir akademik makale de\u011fildi - en iyi s\u0131n\u0131f kanser terapisi olma potansiyelinin arkas\u0131ndaki bilimi sergiledi.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Nuvalent Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>30 A\u011fustos 2025 itibar\u0131yla Nuvalent, Inc. (NUVL) NASDAQ borsas\u0131nda hisse ba\u015f\u0131na <strong>74,93 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse, klinik a\u015famadaki biyoteknoloji \u015firketlerine \u00f6zg\u00fc ola\u011fan\u00fcst\u00fc volatilite g\u00f6sterdi; 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 55,54 $ ile 113,51 $ aras\u0131nda de\u011fi\u015fiyor &#8211; bu, d\u00fc\u015f\u00fck ve y\u00fcksek fiyatlar aras\u0131nda %100&#8217;den fazla fark demek!<\/p>\n<p><strong>Takviminize Not Edin: 11 Kas\u0131m 2025<\/strong>, NUVL yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirket bu tarihte 2025 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak ve ge\u00e7mi\u015fte bu t\u00fcr raporlar hisse fiyat\u0131nda dramatik hareketlere yol a\u00e7abiliyor.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131n\u0131n NUVL Hissesi \u00dczerindeki Etkisi<\/h3>\n<p>Son d\u00f6neme bak\u0131ld\u0131\u011f\u0131nda, \u00f6nemli duyurular etraf\u0131nda belirgin fiyat hareketleri g\u00f6r\u00fcl\u00fcyor:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>7 A\u011fustos 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>78,50 $<\/td>\n<td>-%4,5 (EPS tahminleri ka\u00e7\u0131r\u0131ld\u0131)<\/td>\n<\/tr>\n<tr>\n<td>8 May\u0131s 2025<\/td>\n<td>Klinik Deneme G\u00fcncellemesi<\/td>\n<td>72,30 $<\/td>\n<td>+%18,2 (pozitif veriler)<\/td>\n<\/tr>\n<tr>\n<td>27 \u015eubat 2025<\/td>\n<td>2024 4. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>68,90 $<\/td>\n<td>+%9,8 (\u00fcr\u00fcn hatt\u0131 ilerlemesi)<\/td>\n<\/tr>\n<tr>\n<td>9 Kas\u0131m 2024<\/td>\n<td>FDA Ba\u015fvuru Haberi<\/td>\n<td>65,40 $<\/td>\n<td>+%22,1 (kademeli NDA kabul\u00fc)<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fustos 2024<\/td>\n<td>2024 2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>62,10 $<\/td>\n<td>+%11,3 (g\u00fc\u00e7l\u00fc \u00fcr\u00fcn hatt\u0131 g\u00fcncellemeleri)<\/td>\n<\/tr>\n<tr>\n<td>10 May\u0131s 2024<\/td>\n<td>Faz 1 Verileri<\/td>\n<td>58,20 $<\/td>\n<td>+%6,8 (cesaret verici sonu\u00e7lar)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>E\u011filim Analizi<\/strong>: Pozitif klinik deneme g\u00fcncellemeleri ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 genellikle en b\u00fcy\u00fck kazan\u00e7lar\u0131 (%18-22) getirirken, kazan\u00e7 ka\u00e7\u0131rmalar\u0131 ge\u00e7ici %4-5 d\u00fc\u015f\u00fc\u015flere neden oluyor. Bu desen, NUVL yat\u0131r\u0131mc\u0131lar\u0131n\u0131n \u00e7eyreklik finansallardan \u00e7ok klinik geli\u015fmelere odaklanmas\u0131 gerekti\u011fini g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2>\n<p>Nuvalent hisseleri son alt\u0131 ayda <strong>%27,8 art\u0131\u015f<\/strong> ya\u015fad\u0131, ancak yolculuk sorunsuz de\u011fildi:<\/p>\n<ul>\n<li><strong>\u015eubat 2025<\/strong>: 62,50 $ &#8211; Tatil sonras\u0131 konsolidasyon d\u00f6nemi<\/li>\n<li><strong>Mart 2025<\/strong>: 71,80 $ &#8211; ALKAZAR Faz 3 deneme ba\u015flang\u0131c\u0131yla art\u0131\u015f<\/li>\n<li><strong>Nisan 2025<\/strong>: 68,20 $ &#8211; Mart rallisi sonras\u0131 kar realizasyonu<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 83,40 $ &#8211; ASCO toplant\u0131s\u0131nda klinik veri sunumu<\/li>\n<li><strong>Haziran 2025<\/strong>: 76,10 $ &#8211; Piyasa genelinde biyoteknoloji sekt\u00f6r\u00fc d\u00fczeltmesi<\/li>\n<li><strong>Temmuz 2025<\/strong>: 79,60 $ &#8211; FDA RTOR program\u0131na kat\u0131l\u0131m heyecan\u0131<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 74,93 $ &#8211; 2. \u00e7eyrek kazan\u00e7 ka\u00e7\u0131rmas\u0131 hevesi azaltt\u0131<\/li>\n<\/ul>\n<p>Volatilitenin sebebi nedir? NUVL, &#8220;OnTarget 2026&#8221; stratejisini birden fazla klinik d\u00f6n\u00fcm noktas\u0131yla uyguluyor. \u015eirket, neladalkib ile standart tedavi alectinib&#8217;i kar\u015f\u0131la\u015ft\u0131ran kritik ALKAZAR Faz 3 denemesini ba\u015flat\u0131rken, zidesamtinib i\u00e7in kademeli NDA ba\u015fvurusunu da ilerletiyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Yolu<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve \u00fcr\u00fcn hatt\u0131 ilerlemesine g\u00f6re beklentiler \u015funlar:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 95-110 $ (FDA ba\u015fvuru tamamlanmas\u0131 ve klinik veri a\u00e7\u0131klamalar\u0131) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/li>\n<li><strong>2026<\/strong>: 130-160 $ (Olas\u0131 ilk FDA onay\u0131 ve ticarile\u015fme lansman\u0131)<\/li>\n<li><strong>2028<\/strong>: 220-280 $ (\u00c7oklu \u00fcr\u00fcn lansmanlar\u0131 ve pazar geni\u015flemesi)<\/li>\n<li><strong>2030<\/strong>: 350-450 $ (K\u00f6kl\u00fc ticari varl\u0131k ve \u00fcr\u00fcn hatt\u0131 olgunla\u015fmas\u0131)<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: NUVL, klasik y\u00fcksek risk-y\u00fcksek getiri biyoteknoloji f\u0131rsat\u0131n\u0131 temsil ediyor. 13 analistin al\u0131m tavsiyesi verdi\u011fi ve fiyat hedeflerinin 100 $ ile 140 $ aras\u0131nda de\u011fi\u015fti\u011fi (<a href=\"https:\/\/www.directorstalkinterviews.com\/nuvalent-inc-nuvl-stock-analysis-a-biotech-contender-with-52-potential-upside\/4121213505\">DirectorTalk Interviews<\/a>) konsens\u00fcs, mevcut seviyelerden yakla\u015f\u0131k %52 y\u00fckseli\u015f potansiyeli oldu\u011funu g\u00f6steriyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: NUVL&#8217;nin \u00fc\u00e7 \u00f6nc\u00fc aday\u0131 (NVL-520, NVL-655, NVL-330) etkinlik veya g\u00fcvenlik hedeflerini kar\u015f\u0131layamayabilir<\/li>\n<li><strong>FDA Reddetmesi<\/strong>: Kademeli NDA ba\u015fvurusuna ra\u011fmen FDA ek veri veya \u00e7al\u0131\u015fmalar talep edebilir<\/li>\n<li><strong>Nakit Yak\u0131m\u0131<\/strong>: -121 milyon $ negatif serbest nakit ak\u0131\u015f\u0131 dikkatli sermaye y\u00f6netimi gerektirir<\/li>\n<li><strong>Piyasa Volatilitesi<\/strong>: 1,30 beta de\u011feri, genel piyasadan %30 daha volatil oldu\u011fu anlam\u0131na gelir<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>FDA \u0130vmelenmesi<\/strong>: Ger\u00e7ek Zamanl\u0131 Onkoloji \u0130nceleme program\u0131na kat\u0131l\u0131m s\u00fcreci h\u0131zland\u0131r\u0131yor<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 Derinli\u011fi<\/strong>: \u00dc\u00e7 klinik a\u015fama aday\u0131 birden fazla ba\u015far\u0131 \u015fans\u0131 sunuyor<\/li>\n<li><strong>Pazar \u0130htiyac\u0131<\/strong>: Tedaviye diren\u00e7li kanserler 15 milyar $&#8217;dan fazla pazar f\u0131rsat\u0131 yarat\u0131yor<\/li>\n<li><strong>Analist Deste\u011fi<\/strong>: 13 analistin oybirli\u011fiyle al\u0131m tavsiyesi<\/li>\n<li><strong>Nakit Rezervi<\/strong>: 1 milyar $ nakit pozisyonu operasyonlar\u0131 2028&#8217;e kadar finanse ediyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5&#8217;inden fazlas\u0131n\u0131 NUVL gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yapmak yerine, birka\u00e7 hafta boyunca k\u00fc\u00e7\u00fck miktarlarda al\u0131m yap\u0131n<\/li>\n<li><strong>11 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7 tarihini i\u015faretleyin ve \u00f6nemli fiyat hareketlerine kar\u015f\u0131 haz\u0131r olun<\/li>\n<li><strong>\u00c7e\u015fitlendirin<\/strong>: NUVL&#8217;yi daha istikrarl\u0131 sa\u011fl\u0131k hisseleri veya ETF&#8217;lerle dengeleyin<\/li>\n<\/ol>\n<p>Espiri: &#8220;NUVL ticareti yapmak, bir t\u0131bbi drama izlemek gibidir &#8211; bolca gerilim, ara s\u0131ra kalp krizi, ama sezon finali muhte\u015fem olabilir!&#8221;<\/p>\n<h2>\u2705 Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeli hisseler ve par\u00e7al\u0131 hisse sunan bir platform se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;NUVL&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Sadece &#8220;Nuvalent&#8221; de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretlerini kontrol edin &#8211; i\u015flem de\u011ferinin %1&#8217;inden az olmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td>\n<td>70 $ destek ve 80 $ diren\u00e7 gibi kritik seviyeleri izleyin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td>\n<td>K\u00e2r alaca\u011f\u0131n\u0131z veya zarar kesme yapaca\u011f\u0131n\u0131z zaman\u0131 \u00f6nceden belirleyin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Tezinizi Belgeleyin<\/td>\n<td>Duygusal kararlar almamak i\u00e7in neden ald\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>\u015eirket Haberlerini Takip Edin<\/td>\n<td>&#8220;Nuvalent&#8221; ve &#8220;NVL-520&#8221; i\u00e7in Google uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>\u00c7eyreklik \u0130nceleme Yap\u0131n<\/td>\n<td>Her kazan\u00e7 raporundan sonra yat\u0131r\u0131m\u0131n\u0131z\u0131 yeniden de\u011ferlendirin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Neden Yeni NUVL Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>Nuvalent gibi yenilik\u00e7i \u015firketlere yat\u0131r\u0131m yapmak isteyenler i\u00e7in Pocket Option, yeni ba\u015flayan yat\u0131r\u0131mc\u0131lara m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunuyor:<\/p>\n<ul>\n<li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> &#8211; Yat\u0131r\u0131m tezini test etmek i\u00e7in c\u00fczdan\u0131n\u0131zda kalan k\u00fc\u00e7\u00fck bir miktarla ba\u015flayabilirsiniz. Bu, NUVL gibi volatil hisselerde yava\u015f yava\u015f yat\u0131r\u0131m yapmak isteyenler i\u00e7in \u00e7ok \u00f6nemli.<\/li>\n<li><strong>\u015eim\u015fek H\u0131z\u0131nda Do\u011frulama<\/strong> &#8211; Tek bir belge ile KYC i\u015flemini bir dakikadan k\u0131sa s\u00fcrede tamamlay\u0131n. Klinik deneme sonu\u00e7lar\u0131 veya FDA duyurular\u0131 gibi zaman hassasiyeti olan f\u0131rsatlarda uzun onay s\u00fcre\u00e7leri nedeniyle f\u0131rsatlar\u0131 ka\u00e7\u0131rmazs\u0131n\u0131z.<\/li>\n<li><strong>100&#8217;den Fazla Para \u00c7ekme Y\u00f6ntemi<\/strong> &#8211; Kripto paralardan e-c\u00fczdanlara ve geleneksel banka transferlerine kadar, NUVL potansiyeliniz ger\u00e7ekle\u015fti\u011finde kazan\u00e7lar\u0131n\u0131za eri\u015fimde esneklik sa\u011flar.<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, NUVL pozisyonunuzu ger\u00e7ek zamanl\u0131 grafikler ve haber entegrasyonu ile kolayca takip etmenizi sa\u011flar; b\u00f6ylece yat\u0131r\u0131m\u0131n\u0131z\u0131 etkileyen kritik geli\u015fmelerden haberdar olursunuz.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Nuvalent: Hassas Onkoloji \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Nuvalent, kanser tedavisinde bir devrimin \u00f6nc\u00fcs\u00fcd\u00fcr. \u015eirket sadece ba\u015fka bir kemoterapi ilac\u0131 geli\u015ftirmiyor &#8211; mevcut tedavilerin s\u0131n\u0131rlamalar\u0131n\u0131 a\u015fmak i\u00e7in hassas \u015fekilde hedeflenmi\u015f terapiler yarat\u0131yor. Tedaviye diren\u00e7li kanserlerde kinaz hedeflerine odaklanmalar\u0131, onkolojide en b\u00fcy\u00fck kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lardan birini ele al\u0131yor.<\/p>\n<p>162 \u00e7al\u0131\u015fan\u0131 ve Massachusetts, Cambridge merkezli operasyonlar\u0131yla Nuvalent, bir startup \u00e7evikli\u011fiyle iddial\u0131 klinik programlar\u0131 y\u00fcr\u00fct\u00fcyor; bu programlar kanser bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilir. \u015eirketin \u00f6nc\u00fc \u00fcr\u00fcn adaylar\u0131 ROS1-pozitif NSCLC, ALK-pozitif NSCLC ve HER2-de\u011fi\u015ftirilmi\u015f kanserleri hedefliyor &#8211; mevcut tedavilerin diren\u00e7 mekanizmalar\u0131 nedeniyle s\u0131kl\u0131kla ba\u015far\u0131s\u0131z oldu\u011fu alanlar.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Nuvalent bilim insanlar\u0131, zidesamtinib&#8217;in yeni bir ROS1-selektif inhibit\u00f6r olarak rasyonel molek\u00fcler tasar\u0131m yakla\u015f\u0131m\u0131n\u0131 nas\u0131l olu\u015fturdu\u011funu g\u00f6steren \u00e7\u0131\u011f\u0131r a\u00e7an bir ara\u015ft\u0131rmay\u0131 Molecular Cancer Therapeutics dergisinde yay\u0131mlad\u0131 (<a href=\"https:\/\/investors.nuvalent.com\/2025-04-29-Nuvalent-Announces-Publication-in-Molecular-Cancer-Therapeutics-Reinforcing-Rational-Molecular-Design-of-Zidesamtinib-as-a-Novel-ROS1-Selective-Inhibitor\">\u015eirket Duyurusu<\/a>). Bu sadece ba\u015fka bir akademik makale de\u011fildi &#8211; en iyi s\u0131n\u0131f kanser terapisi olma potansiyelinin arkas\u0131ndaki bilimi sergiledi.<\/p>\n"},"faq":[{"question":"Nuvalent, Inc. (NUVL) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"NUVL hisselerini sat\u0131n almak i\u00e7in NASDAQ listeli bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"NUVL\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve fiyat uyar\u0131lar\u0131 kurarak piyasay\u0131 takip edin."},{"question":"NUVL hisselerinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, FDA reddi, y\u00fcksek nakit yak\u0131m\u0131 ve piyasa volatilitesi bulunmaktad\u0131r."},{"question":"NUVL hisseleri i\u00e7in fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 95-110 $, 2026'da 130-160 $, 2028'de 220-280 $ ve 2030'da 350-450 $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"Yeni ba\u015flayanlar NUVL hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn %3-5'inden fazlas\u0131n\u0131 ay\u0131rmamak, dolar maliyet ortalamas\u0131 yapmak, \u00f6nemli tarihleri takip etmek ve portf\u00f6y\u00fc \u00e7e\u015fitlendirmek \u00f6nerilir."},{"question":"Pocket Option NUVL yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi sunmas\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Nuvalent, Inc. (NUVL) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"NUVL hisselerini sat\u0131n almak i\u00e7in NASDAQ listeli bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"NUVL\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve fiyat uyar\u0131lar\u0131 kurarak piyasay\u0131 takip edin."},{"question":"NUVL hisselerinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, FDA reddi, y\u00fcksek nakit yak\u0131m\u0131 ve piyasa volatilitesi bulunmaktad\u0131r."},{"question":"NUVL hisseleri i\u00e7in fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 95-110 $, 2026'da 130-160 $, 2028'de 220-280 $ ve 2030'da 350-450 $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"Yeni ba\u015flayanlar NUVL hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn %3-5'inden fazlas\u0131n\u0131 ay\u0131rmamak, dolar maliyet ortalamas\u0131 yapmak, \u00f6nemli tarihleri takip etmek ve portf\u00f6y\u00fc \u00e7e\u015fitlendirmek \u00f6nerilir."},{"question":"Pocket Option NUVL yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi sunmas\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-30T08:48:13+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-30T08:48:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/\",\"name\":\"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-30T08:48:13+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/","og_locale":"tr_TR","og_type":"article","og_title":"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-30T08:48:13+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-30T08:48:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/","name":"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-30T08:48:13+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nuvalent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Nuvalent, Inc. (NUVL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nuvalent, Inc. (NUVL) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":359330,"slug":"how-to-buy-nuvalent","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Nuvalent, Inc. (NUVL) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Nuvalent, Inc. (NUVL)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-nuvalent\/"},"pt_AA":{"locale":"pt_AA","id":359326,"slug":"how-to-buy-nuvalent","post_title":"Como comprar a\u00e7\u00f5es da Nuvalent, Inc. (NUVL) - Investimento em a\u00e7\u00f5es da Nuvalent, Inc. (NUVL)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-nuvalent\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/359331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=359331"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/359331\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=359331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=359331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=359331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}